We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

274 hedge funds and large institutions have $3.63B invested in Ultragenyx Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 117 increasing their positions, 80 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

52% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $15M

46% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 80

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

2% more funds holding

Funds holding: 269 → 274 (+5)

0.33% more ownership

Funds ownership: 97.06% → 97.4% (+0.33%)

3% less capital invested

Capital invested by funds: $3.73B → $3.63B (-$103M)

Holders
274
Holders Change
+5
Holders Change %
+1.86%
% of All Funds
3.96%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
47
Increased
117
Reduced
80
Closed
40
Calls
$22.7M
Puts
$15M
Net Calls
+$7.77M
Net Calls Change
-$6.85M

Top Buyers

1
VPC
Vestal Point Capital
New York
+$72.2M
2
Sands Capital Management
Sands Capital Management
Virginia
+$63.8M
3
Millennium Management
Millennium Management
New York
+$48.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$46.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$41.6M

Top Sellers

1
RI
RTW Investments
New York
-$163M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$24.6M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$20.5M
4
EAM
Eventide Asset Management
Massachusetts
-$16.8M
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$9.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Neuberger Berman Group
276
Neuberger Berman Group
New York
– -$4.9M -104,939 Closed
LCM
277
Laurion Capital Management
New York
– -$3.17M -68,000 Closed
DA
278
Duality Advisers
Florida
– -$1.87M -39,977 Closed
ECM
279
ExodusPoint Capital Management
New York
– -$1.77M -38,025 Closed
Balyasny Asset Management
280
Balyasny Asset Management
Illinois
– -$1.34M -28,743 Closed
PHK
281
Point72 Hong Kong
Hong Kong
– -$1.26M -27,004 Closed
SFI
282
Susquehanna Fundamental Investments
Pennsylvania
– -$1.07M -23,005 Closed
CSS
283
Cubist Systematic Strategies
Connecticut
– -$1.06M -22,631 Closed
ACP
284
Acuta Capital Partners
California
– -$934K -20,000 Closed
GTC
285
Ghost Tree Capital
New York
– -$934K -20,000 Closed
EAM
286
Exome Asset Management
New York
– -$831K -17,800 Closed
HSBC Holdings
287
HSBC Holdings
United Kingdom
– -$810K -17,349 Closed
DTL
288
Dynamic Technology Lab
Singapore
– -$734K -15,712 Closed
BCM
289
Bayesian Capital Management
New York
– -$714K -15,302 Closed
TRSOTSOK
290
Teachers Retirement System of the State of Kentucky
Kentucky
– -$691K -14,792 Closed
AC
291
AXQ Capital
New Jersey
– -$682K -14,600 Closed
A
292
AlphaQuest
New York
– -$538K -11,522 Closed
BHCM
293
Brevan Howard Capital Management
Jersey
– -$424K -9,077 Closed
WG
294
Winton Group
United Kingdom
– -$409K -8,755 Closed
HF
295
HRT Financial
New York
– -$367K -7,869 Closed
GAM
296
Gotham Asset Management
New York
– -$349K -7,478 Closed
SC
297
Savant Capital
Illinois
– -$338K -7,245 Closed
TCM
298
Teza Capital Management
Illinois
– -$247K -5,293 Closed
CIC
299
Cornercap Investment Counsel
Georgia
– -$241K -5,161 Closed
Capstone Investment Advisors
300
Capstone Investment Advisors
New York
– -$227K -4,863 Closed
9 10 11
12
13

RARE Hedge Fund Activity: Q2 2024 in Review

274 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2024, worth a combined $3.63B — down 2.8% from $3.73B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RARE positions and 40 closed out — a net gain of 7 holders — while 117 added to existing stakes and 80 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $72.2M. The largest seller was RTW Investments, cutting an estimated $163M.

  • 274 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2024, up from 269 in Q1 2024.
  • Funds reported $3.63B of Ultragenyx Pharmaceutical stock for Q2 2024, down 2.8% quarter-over-quarter.
  • 47 funds opened new Ultragenyx Pharmaceutical positions in Q2 2024 and 40 closed out, a net change of +7 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2024 was Vestal Point Capital, an estimated $72.2M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2024 was RTW Investments, an estimated $163M sold.

Based on aggregated 13F filings for Q2 2024.